Abstract: Neurotrophic receptor tyrosine kinase (NTRK) gene fusions are found at a higher frequency, predominantly in pediatric tumors than in adult tumors. In some specific pediatric tumor types, including infantile fibrosarcoma (IFS), congenital mesoblastic nephroma (CMN), and secretory carcinoma of the breast or salivary glands, NTRK gene fusions are present with an abnormally high frequency. Larotrectinib is a first-generation, highly selective oral tropomyosin receptor kinase inhibitor (TRK). In China, it is currently marketed as a capsule dosage form and oral liquid preparation. The Pediatric Oncology Committee of China Anti-Cancer Association and Chinese Research Hospital Association formulated this consensus based on evidence-based medicine, aiming to provide normative guidance for pediatric clinicians to use larotrectinib and provide ideas for further clinical research.